Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.

de Groot AF, Blok EJ, Charehbili A, Engels CC, Smit VTHBM, Dekker-Ensink NG, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Liefers GJ, Nortier JWR, Kuppen PJK, van der Burg SH, Kroep JR.

Breast Cancer Res Treat. 2019 Jun;175(3):605-615. doi: 10.1007/s10549-019-05195-y. Epub 2019 Mar 13.

2.

Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.

Blok EJ, van den Bulk J, Dekker-Ensink NG, Derr R, Kanters C, Bastiaannet E, Kroep JR, van de Velde CJ, Kuppen PJ.

Oncotarget. 2017 Feb 28;8(9):15610-15620. doi: 10.18632/oncotarget.14779.

3.

HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases.

Swets M, König MH, Zaalberg A, Dekker-Ensink NG, Gelderblom H, van de Velde CJ, van den Elsen PJ, Kuppen PJ.

Hum Immunol. 2016 Sep;77(9):773-9. doi: 10.1016/j.humimm.2016.03.001. Epub 2016 Mar 8.

PMID:
26968946
4.

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.

Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3.

5.

High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.

Derr RS, van Hoesel AQ, Benard A, Goossens-Beumer IJ, Sajet A, Dekker-Ensink NG, de Kruijf EM, Bastiaannet E, Smit VT, van de Velde CJ, Kuppen PJ.

BMC Cancer. 2014 Aug 20;14:604. doi: 10.1186/1471-2407-14-604.

6.

Expression of cell adhesion molecules and prognosis in breast cancer.

Saadatmand S, de Kruijf EM, Sajet A, Dekker-Ensink NG, van Nes JG, Putter H, Smit VT, van de Velde CJ, Liefers GJ, Kuppen PJ.

Br J Surg. 2013 Jan;100(2):252-60. doi: 10.1002/bjs.8980. Epub 2012 Nov 22.

PMID:
23175431
7.

Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence.

Doekhie FS, Morreau H, de Bock GH, Speetjens FM, Dekker-Ensink NG, Putter H, van de Velde CJ, Tollenaar RA, Kuppen PJ.

Cancer Microenviron. 2008 Dec;1(1):141-51. doi: 10.1007/s12307-008-0014-3. Epub 2008 Aug 6.

8.

Clinical impact of HLA class I expression in rectal cancer.

Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, van Buren MM, van Velzen M, Dekker-Ensink NG, van de Velde CJ, Kuppen PJ.

Cancer Immunol Immunother. 2008 May;57(5):601-9. Epub 2007 Sep 15.

9.

Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy.

de Heer P, Gosens MJ, de Bruin EC, Dekker-Ensink NG, Putter H, Marijnen CA, van den Brule AJ, van Krieken JH, Rutten HJ, Kuppen PJ, van de Velde CJ; Dutch Colorectal Cancer Group.

Clin Cancer Res. 2007 May 15;13(10):2955-60.

Supplemental Content

Loading ...
Support Center